Clinical and Translational Radiation Oncology最新文献

{"title":"Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose","authors":"S.E. Alexander ,&nbsp;R.A. Mitchell ,&nbsp;A. Dunlop ,&nbsp;T. Herbert ,&nbsp;K. Morrison ,&nbsp;J. Nartey ,&nbsp;U. Oelfke ,&nbsp;H.A. McNair ,&nbsp;A.C. Tree","doi":"10.1016/j.ctro.2025.100985","DOIUrl":"10.1016/j.ctro.2025.100985","url":null,"abstract":"<div><h3>Introduction</h3><div>Magnetic resonance image-guided adaptive radiotherapy (MRIgART) reduces uncertainties by correcting for day-to-day target and organ-at-risk deformation and motion. This is the first study to examine the dosimetric impact of MRIgART for ultrahypofractionated prostate cancer treatment, compared to standard-of-care image-guided non-adapted radiotherapy.</div></div><div><h3>Methods</h3><div>Twenty patients with localised prostate cancer, who received ultrahypofractionated MRIgART on the Unity MR linac (Elekta, Sweden) were retrospectively analysed. Online daily MRI was acquired for replanning (MRI_session) and a second for position verification before treatment (MRI_verification). To compare delivered dose with and without adaptation, three plans were generated offline per fraction; a session plan (reference plan adapted to MRI_session anatomy), a verification plan (session plan recalculated on MRI_verfication anatomy), and a non-adapted plan (reference plan recalculated on MRI_verfication anatomy). Target and organ-at-risk doses were calculated, and dose difference evaluated.</div><div>Secondary analysis, using deformable dose accumulation, estimated verification and non-adapted dose to primary target (CTVpsv) substructures; prostate, gross tumour volume (GTV) and proximal 1 cm of seminal vesicles (1cmSV). Impact of prostate, rectum and bladder volume changes on dose were evaluated.</div></div><div><h3>Results</h3><div>Median dose to 95 % of the CTVpsv was significantly higher with adaptation; 40.3, 40.0 and 38.2 Gy for session, verification, and non-adapted plans. Adaptation achieved a lower median urethra V42Gy dose but bladder V37Gy dose was lower when not adapting. Rectum V36Gy dose was similar for adapted and non-adapted plans.</div><div>CTVpsv substructure dose difference was greatest for 1cmSV; 40.0 versus 37.5 Gy for verification/non-adapted plans. Adaptation achieved significantly higher prostate only, but not GTV doses. Prostate and rectal volume changes had a negative impact on non-adapted dose only.</div></div><div><h3>Conclusion</h3><div>MRIgART, offers significant dosimetric benefit for ultrahypofractionated prostate cancer compared to non-adapted strategies. Greatest benefit is expected for those with SV or high-risk of SV involvement, persistent rectal gas, prostate swelling and for the application of novel dose strategies including GTV dose escalation and non-involved prostate dose de-escalation.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100985"},"PeriodicalIF":2.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bulky non-small cell lung cancer treated with two-field robust proton lattice boost followed by conventional chemoradiation","authors":"Matthew J. Ferris,&nbsp;Sina Mossahebi,&nbsp;Jenna Jatczak,&nbsp;Jason K. Molitoris,&nbsp;Zaker H. Rana,&nbsp;Katarina J. Steacy,&nbsp;William F. Regine,&nbsp;Byong Yong Yi","doi":"10.1016/j.ctro.2025.100987","DOIUrl":"10.1016/j.ctro.2025.100987","url":null,"abstract":"<div><div>Despite advances in outcomes for non-small cell lung cancer (NSCLC) with the establishment of adjuvant immunotherapy as the standard of care, locoregional recurrence is still experienced by half of patients with progressive disease. We sought to integrate a novel pencil beam scanning (PBS) spatially fractionated approach into definitive management of bulky non-small cell lung cancer cases. Spatial fractionation via lattice or more commonly GRID has long been of interest as supplement to more conventional radiation regimens for bulky tumors, though requirements for plan robustness and concerns about single-field approaches have previously limited their integration into proton therapy practice. Here we present two cases of bulky NSCLC treated with a novel two-field partially robust PBS lattice boost of 12 Gy followed by standard conventional chemoradiation. Both patients experienced usual mild treatment related toxicities and remain with their bulky lesions controlled in field at more than a year out from treatment.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100987"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144289027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor control and survival after postoperative radiotherapy for high-risk oral cavity cancer: A retrospective cohort study","authors":"Pepijn B Bolleurs ,&nbsp;Brend P Jonker ,&nbsp;Joris BW Elbers ,&nbsp;Gerda M Verduijn ,&nbsp;Atilla Gül ,&nbsp;Aniel Sewnaik ,&nbsp;Wilma D Heemsbergen","doi":"10.1016/j.ctro.2025.100988","DOIUrl":"10.1016/j.ctro.2025.100988","url":null,"abstract":"<div><h3>Background</h3><div>We evaluated locoregional failure (LRF) and survival after postoperative radiotherapy (PORT) in selected high-risk oral squamous cell carcinoma (OSCC) patients.</div></div><div><h3>Methods</h3><div>In a retrospective OSCC cohort (n = 219) treated with local (n = 216) and/or regional (n = 87) PORT in 2011–2018, we determined the first location of tumor recurrence or progression, survival, and cause of death. Tumor control and survival was calculated using Kaplan Meier method. Prognostic factors were evaluated in Cox regression models.</div></div><div><h3>Results</h3><div>Main subsites were oral tongue (34 %), gingiva (32 %), and floor of mouth (27 %). Eight percent also received chemotherapy. Median follow-up was five year for tumor control and eight year for survival. Tumor progression was observed in 47 patients (n = 31 LRF). Nine patients had salvage treatment. Locoregional control was 87 % and 84 % at 2 and 5 years, respectively. Significant prognostic factors for local failure (LF) were T4 stage, bone invasion, and subsite gingiva; 12 of 18 LF concerned a T4 gingiva tumor with bone invasion. For regional failure (RF), pN1 (vs pN0) was prognostic, mainly concerning solitary contralateral RFs. Overall survival was 63 % and 48 % at 5 and 8 year, respectively. Main causes of death (104 events) were the index tumor (n = 42) and a post-treatment second primary tumor (n = 37).</div></div><div><h3>Conclusion</h3><div>A locoregional control of 84 % was achieved after PORT for high-risk OSCC with only 8 % receiving additional chemotherapy. Overall survival was 48 % at 8 years, with a large proportion of cancer-related deaths related to the index tumor and other subsequent tumor diagnoses. Risk of LF was increased for gingiva tumors with bone invasion. N1 stage was associated with a risk of solitary contralateral RFs in non-irradiated neck areas.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100988"},"PeriodicalIF":2.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated segmentation of target volumes in breast cancer radiotherapy, impact on target size and dose to organs at risk","authors":"Vivi Tang ,&nbsp;Elinore Wieslander ,&nbsp;Mahnaz Haghanegi ,&nbsp;Elisabeth Kjellén ,&nbsp;Sara Alkner","doi":"10.1016/j.ctro.2025.100986","DOIUrl":"10.1016/j.ctro.2025.100986","url":null,"abstract":"<div><h3>Introduction</h3><div>Target volume delineation is crucial in breast cancer radiotherapy planning but involves significant interobserver variability. Deep learning (DL) models may reduce this variability, saving time and costs. However, current DL-models do not consider clinical data, such as tumor location and patient comorbidity, to adjust the target and reduce dose to organs at risk (OAR). This study compares clinically defined target volumes to those generated by a DL-model in terms of size, geometric overlap, and dose to OAR.</div></div><div><h3>Method</h3><div>For a hypothetical breast cancer patient, we compared target volumes constructed by Swedish radiotherapy clinics and two DL-models, Raystation and MVision. Geometrical overlap was evaluated, as well as the impact of differences in target delineation on dose to OAR. Treatment plans for locoregional vs. breast-only 3D-conformal radiotherapy were generated.</div></div><div><h3>Results</h3><div>CTV-structures for the breast, lymph nodes level I-IV, and internal mammary nodes were available for 10, 11, and 14 centers respectively. Volume of the CTV-breasts varied between 770–890cc, and the total CTV-volumes (breast + lymph nodes) between 875–1003cc. The DL-models did not constitute the largest nor smallest breast or total CTV-volumes, and geometric overlap between structures was relatively good. Evaluating dose to OAR from dose plans based on the respective CTV-volumes for locoregional radiotherapy, this was comparable between the DL-models and the mean of the CTVs generated by the clinics. In radiotherapy of only the breast, the CTV-breasts constructed by the DL-models gave the highest heart doses due to their proximity to the chest wall, affecting field angle choices. No difference was seen in dose to the ipsilateral lung, thyroid gland, or humeral head.</div></div><div><h3>Conclusion</h3><div>DL-models for target delineation have great potential. However, their introduction must be closely monitored since even small differences compared to clinical standards may affect doses to OAR in 3D conformal breast cancer radiotherapy.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100986"},"PeriodicalIF":2.7,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score-matched analysis","authors":"Erkan Topkan ,&nbsp;Efsun Somay ,&nbsp;Ugur Selek","doi":"10.1016/j.ctro.2025.100982","DOIUrl":"10.1016/j.ctro.2025.100982","url":null,"abstract":"","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100982"},"PeriodicalIF":2.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanically assisted non-invasive ventilation for liver SABR: Improve CBCT, treat more accurately","authors":"Julien Pierrard ,&nbsp;Nicolas Audag ,&nbsp;Christel Abdel Massih ,&nbsp;Maria Alvear Garcia ,&nbsp;Enrique Alvarez Moreno ,&nbsp;Andrea Colot ,&nbsp;Simon Jardinet ,&nbsp;Romain Mony ,&nbsp;Ana Francisca Nevez Marques ,&nbsp;Lola Servaes ,&nbsp;Thaïs Tison ,&nbsp;Valentin Van den Bossche ,&nbsp;Aniko Wale Etume ,&nbsp;Lamyae Zouheir ,&nbsp;Geneviève Van Ooteghem","doi":"10.1016/j.ctro.2025.100983","DOIUrl":"10.1016/j.ctro.2025.100983","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Cone-beam computed tomography (CBCT) for image-guided radiotherapy (IGRT) during liver stereotactic ablative radiotherapy (SABR) is degraded by respiratory motion artefacts, potentially jeopardising treatment accuracy. Mechanically assisted non-invasive ventilation-induced breath-hold (MANIV-BH) can reduce these artefacts. This study compares MANIV-BH and free-breathing CBCTs regarding image quality, IGRT variability, automatic registration accuracy, and deep-learning auto-segmentation performance.</div></div><div><h3>Materials and methods</h3><div>Liver SABR CBCTs were presented blindly to 14 operators: 25 patients with FB and 25 with MANIV-BH. They rated CBCT quality and IGRT ease (rigid registration with planning CT). Interoperator IGRT variability was compared between FB and MANIV-BH. Automatic gross tumour volume (GTV) mapping accuracy was compared using automatic rigid registration and image-guided deformable registration. Deep-learning organ-at-risk (OAR) auto-segmentation was rated by an operator, who recorded the time dedicated for manual correction of these volumes.</div></div><div><h3>Results</h3><div>MANIV-BH significantly improved CBCT image quality (“Excellent”/“Good”: 83.4 % versus 25.4 % with FB, p &lt; 0.001), facilitated IGRT (“Very easy”/“Easy”: 68.0 % versus 38.9 % with FB, p &lt; 0.001), and reduced IGRT variability, particularly for trained operators (overall variability of 3.2 mm versus 4.6 mm with FB, p = 0.010). MANIV-BH improved deep-learning auto-segmentation performance (80.0 % rated “Excellent”/“Good” versus 4.0 % with FB, p &lt; 0.001), and reduced median manual correction time by 54.2 % compared to FB (p &lt; 0.001). However, automatic GTV mapping accuracy was not significantly different between MANIV-BH and FB.</div></div><div><h3>Conclusion</h3><div>In liver SABR, MANIV-BH significantly improves CBCT quality, reduces interoperator IGRT variability, and enhances OAR auto-segmentation. Beyond being safe and effective for respiratory motion mitigation, MANIV increases accuracy during treatment delivery, although its implementation requires resources.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100983"},"PeriodicalIF":2.7,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting late renal toxicity using a two-component repair model among pediatric patients receiving total body irradiation for stem cell transplant","authors":"Eric D. Ehler,&nbsp;Grace H. Hutchinson,&nbsp;Jianling Yuan,&nbsp;Kathryn E. Dusenbery","doi":"10.1016/j.ctro.2025.100984","DOIUrl":"10.1016/j.ctro.2025.100984","url":null,"abstract":"<div><h3>Purpose/Objectives</h3><div>Late renal toxicity can be impactful for stem cell transplant (SCT) patients with total body irradiation (TBI) as part of the conditioning regimen. This work describes a two component repair model to predict renal toxicity among pediatric patients.</div></div><div><h3>Materials/Methods</h3><div>Systematic literature searches described in two other reports were used to identify articles describing late renal toxicity in children treated with TBI as part of SCT. Six studies were included with a combined sample size of 172 patients. Data pertaining to TBI and renal toxicity endpoints were extracted. Probability of renal toxicity was analyzed in relation to TBI dose, fractionation, and dose rate. A logistic regression model was developed using studies with sufficient TBI and pediatric outcome data. The toxicity was calculated from reported rates from each study and were primarily based on abnormal laboratory values.</div></div><div><h3>Results</h3><div>Physical dose and a traditional method of calculating EQD2 were tested for a significant dose response relationship although none were found. Instead, a statistically significant relationship was found with a two component sublethal repair EQD2 calculation model using logistic regression (p = 0.03). The model predicted the odds ratio for renal toxicity to be 2.9 Gy⁻¹. Predicted probabilities of 5 %, 10 %, and 50 % clinically significant renal toxicities are associated with EQD2 values of 10.4, 11.1, and 13.2 Gy, respectively.</div></div><div><h3>Conclusions</h3><div>A model to predict the risk of renal toxicity was determined. This model indicates that dose rate and the time interval between fractions are important factors in renal toxicity for pediatric patients receiving SCT with TBI as part of the conditioning regimen.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100984"},"PeriodicalIF":2.7,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A GORTEC survey on low-risk CTV-P2 delineation in head and neck cancers","authors":"Michel Lapeyre ,&nbsp;Yoann Pointreau ,&nbsp;Marc Alfonsi ,&nbsp;Pierre Boisselier ,&nbsp;Julian Biau ,&nbsp;Pierre Blanchard ,&nbsp;Joël Castelli ,&nbsp;Pierre Graff ,&nbsp;Florence Huguet ,&nbsp;Laurent Martin ,&nbsp;Séverine Racadot ,&nbsp;Xu Shan Sun ,&nbsp;Yungan Tao ,&nbsp;Jean Bourhis ,&nbsp;Juliette Thariat","doi":"10.1016/j.ctro.2025.100980","DOIUrl":"10.1016/j.ctro.2025.100980","url":null,"abstract":"<div><h3>Purpose</h3><div>An international consensus was established in 2018 to standardise practice using geometric (5 + 5 mm) expansion around GTV-P for definitive radiotherapy of squamous cell carcinomas of the head and neck (HNC). The GORTEC (French HNC Oncology and Radiotherapy Group) conducted a survey to assess the level of agreement about CTV-P2 delineation using a “formalised consensus method”.</div></div><div><h3>Methods</h3><div>The 32 proposals of the 2018 consensus on CTV-P2 and 6 additional GORTEC proposals were submitted to 13 GORTEC radiation oncologists (RO). Proposals were rated as “suitable” for median scores ≥7, “unsuitable” for scores ≤3.5 or “uncertain.” The degree of agreement was high (≥85 %), moderate (75–84 %) or low (&lt;75 %). Suitable proposals were reviewed by 40 other RO for final recommendations.</div></div><div><h3>Results</h3><div>The 2018 proposals were “uncertain” with low degrees of agreement (41.5–69 %), except for T1 tumors, which had 89 % agreement. Five out of 6 GORTEC proposals were “suitable” and one “uncertain.” The final recommendation was “suitable and to be retained” by 97.5 % of RO, as follows: To obtain CTV-P2, GORTEC recommends applying a “geo-anatomical” approach. Using the geometric concept, 10 mm-isotropic margins are applied to the GTV, for all locations but the hypopharynx (10 mm antero-posterior, laterally and 15 mm craniocaudally). CTV-P2 is further modified using the anatomical concept (anatomical barriers, dissemination routes) and accounting the benefit/risk balance and proximity of organs at risk.</div></div><div><h3>Conclusion</h3><div>The GORTEC survey derived from the 2018 international CTV-Ps delineation consensus suggests a “geo-anatomical” approach for the delineation of CTV-P2 in HNC.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100980"},"PeriodicalIF":2.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SBRT in recurrent oligometastatic ovarian cancer: An EORTC Y-ECI GCG systematic review","authors":"Constance Huck ,&nbsp;Melpomeni Kountouri ,&nbsp;Ramon Yarza ,&nbsp;Gloria Marquina ,&nbsp;Manuel Espantaleon ,&nbsp;Judith Kroep ,&nbsp;Fernanda Herrera ,&nbsp;Ainhoa Madariaga ,&nbsp;Noelia Sanmamed","doi":"10.1016/j.ctro.2025.100981","DOIUrl":"10.1016/j.ctro.2025.100981","url":null,"abstract":"<div><div>Managing recurrent oligometastatic ovarian cancer with a limited disease burden is challenging, requiring localized treatments to achieve durable control while reducing systemic therapy exposure. Stereotactic body radiotherapy (SBRT) offers high precision and ablative dosing, minimizing toxicity to adjacent organs. This systematic review analyzed nine studies involving 426 patients and 809 lesions treated with SBRT. Patients had a median age of 61.2 years and underwent a median of three prior systemic treatments. SBRT, delivered at a median dose of 40 Gy, achieved a pooled median progression-free survival (PFS) of 10.32 months (95 % CI: 2.79–38.26) and a 2-year overall survival rate of 78 %. Local outcomes were promising, with a target lesion control rate of 95.9 % and a lesion response rate of 86 %. SBRT delayed systemic therapy initiation, with a median time of 9.45 months, and was well tolerated, with mostly mild toxicities (CTCAE grade ≤ 2). Rare grade 3 and 5 gastrointestinal toxicities were reported. Despite these encouraging results, the studies were limited by moderate to serious risk of bias, heterogeneity in treatment protocols, and variations in SBRT dose and fractionation. These findings highlight SBRT’s potential as an effective treatment for oligometastatic ovarian cancer, but further research is needed to refine strategies, standardize regimens, and identify patient subgroups most likely to benefit. Prospective trials are eagerly awaited to establish SBRT’s role in improving outcomes for this challenging clinical scenario.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100981"},"PeriodicalIF":2.7,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro measurement of proton RBE: A multi-centric comparison using a harmonized setup","authors":"Olga Sokol ,&nbsp;Anders Tobias Frederiksen ,&nbsp;Mateusz Sitarz ,&nbsp;Brita Singers Sørensen ,&nbsp;Elham Santina ,&nbsp;Christopher Smith ,&nbsp;John-William Warmenhoven ,&nbsp;Marie Davídková ,&nbsp;Anna Jelínek Michaelidesová ,&nbsp;Irina Danilová ,&nbsp;Oldřich Zahradníček ,&nbsp;Amélia Maia Leite ,&nbsp;Ludovic de Marzi ,&nbsp;Frederic Pouzoulet ,&nbsp;Paweł Olko ,&nbsp;Justyna Miszczyk ,&nbsp;Barbara Orzechowska ,&nbsp;Eleftherios Papalanis ,&nbsp;Mehran Hariri ,&nbsp;Diana Spiegelberg ,&nbsp;Marco Durante","doi":"10.1016/j.ctro.2025.100978","DOIUrl":"10.1016/j.ctro.2025.100978","url":null,"abstract":"<div><h3>Background and purpose</h3><div>This study presents a multi-center comparison of in vitro cell survival measurements and RBE calculations following proton irradiations conducted under harmonized experimental conditions across six European institutions participating in the INSPIRE framework.</div></div><div><h3>Materials and methods</h3><div>V79-4 cells were irradiated using spread-out Bragg peak (SOBP) proton fields of two configurations delivering 6 and 8 Gy with widths of 6 and 4 cm, respectively. Each center adhered to a standardized protocol, utilizing the same phantom design to minimize uncertainties related to sample positioning. X-ray reference irradiations were also performed to assess cell radiosensitivity across the participating centers.</div></div><div><h3>Results</h3><div>Despite the consistent protocol, significant inter-institutional variability was observed in the survival measurements. For both treatment plans, the largest variation was detected in the most distal points of the SOBP (coefficients of variation of 43 % and 60 % for the 6 Gy and 8 Gy plans, respectively). Kruskal-Wallis statistical test confirmed the significant differences between the centers for each of the measured position in the proton field for both SOBP configurations. Discrepancies were observed in calculated RBE data as well, albeit preserving the expected trend for the values to slightly increase towards the distal edge of the SOBP (up to 1.5 and 1.3 for the 6 Gy and 8 Gy plans, respectively).</div></div><div><h3>Conclusion</h3><div>The results of the study highlight the minimal biological variation one could expect performing proton RBE measurements in well-aligned experimental conditions and challenges in conducting large-scale, multi-center radiobiological experiments and inter-comparisons between literature data sets.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"53 ","pages":"Article 100978"},"PeriodicalIF":2.7,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143943110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}